Shire has acquired Swedish biotech firm Premacure. Premacure is developing a protein replacement therapy for prevention of retinopathy of prematurity, a potentially blinding eye disease in premature babies. The acquisition is expected to strengthen Shire's rare disease drug business and extend its product offerings into neonatology.